Blueprint Medicines Corp

Blueprint Medicines Corp is a biopharmaceutical company that specializes in developing precision therapies for patients with genomically defined diseases. Their approach is based on a thorough understanding of the genetic drivers of disease, enabling them to create targeted therapies that address specific molecular abnormalities. The company's pipeline includes multiple programs in various stages of development, including small molecule and biologic therapies. Their lead product candidate, Ayvakit, is a precision therapy for patients with advanced gastrointestinal stromal tumors (GIST) who have a specific genetic mutation. Blueprint Medicines Corp is dedicated to advancing precision medicine and improving outcomes for patients with genomically defined diseases.